Slots fill quickly, and not every site is recruiting at any given moment
"Zepbound (tirzepatide) Obstructive Sleep Apnea Only: Prior Authorization." Policy P 1475-1, effective July 1, 2025 (P&T approved March 2025)
The company reaffirmed its full-year 2024 revenue guidance of $58.5 billion to $61.5 billion and raised its adjusted diluted EPS guidance to $2.15 to $2.35, up from previous estimates of $2.05 to $2.25 versus $2.21 consensus estimates
Outside of the VHA, some states, including California, Washington, and Montana, have demonstrated the ability to initiate large-scale CM implementation efforts." To view or add a comment, sign in "While [contingency management] is best supported for [stimulant use disorder], research supports its use for alcohol, opioid, tobacco, and cannabis use disorders
Common symptoms include fatigue, insomnia, and lethargy